Breast Cancer

Patients with early breast cancer and a low Oncotype DX Recurrence Score (RS) can be safely treated with hormone therapy alone and avoid chemotherapy, according to results of the National Cancer Institute–sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial.
Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA.
In patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
A small study indicates that many patients with breast cancer are not informed about lymphedema as a possible treatment-related side effect and do not know how to recognize its symptoms.
In breast cancer patients with bone metastasis, less frequent infusion of zoledronic acid was as effective as the standard monthly dose, the randomized OPTIMIZE-2 study showed.
In patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
In breast cancer patients with bone metastasis, less frequent infusion of zoledronic acid was as effective as the standard monthly dose, the randomized OPTIMIZE-2 study showed.
For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity.
Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a premeeting Press Cast for the American Society of Clinical Oncology Breast Cancer Symposium held in San Francisco, California.
For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity.
Page 3 of 12
Results 21 - 30 of 116